jcm-logo

Journal Browser

Journal Browser

Improving Cognitive Functioning in People with Schizophrenia

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Mental Health".

Deadline for manuscript submissions: closed (15 November 2019) | Viewed by 20878

Special Issue Editors


E-Mail
Guest Editor
Assistant Professor of Psychiatry, Barcelona Bipolar and Depressive Disorders Program, Hospital Clinic, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain
Interests: psychosis; bipolar disorder; depressive disorder; functioning; staging; precision psychiatry; cognitive remediation; early intervention; procognitive drugs; gut microbiota

grade E-Mail Website
Guest Editor
Barcelona Bipolar and Depressive Disorders Program, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, 08036 Barcelona, Spain
Interests: psychosis; bipolar disorder; depressive disorder; functioning; staging; precision psychiatry; cognitive remediation; psychoeducation; early intervention; procognitive drugs; drug development
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Schizophrenia is a chronic disorder characterized by psychotic symptoms such as hallucinations, delusions and disorganization and negative symptoms such as apathy and social withdrawal. It is also characterized by cognitive dysfunctions, which are present from the onset or even before the onset of the disorder. Cognitive impairment predicts disability and poor general functioning in the daily life of people diagnosed with schizophrenia. Although cognition is not a formal part of the current diagnostic criteria for schizophrenia, it is considered as a core feature of this illness.

Impairments in a broad range of cognitive domains have been consistently reported in individuals with schizophrenia, and persist throughout the course of the illness. Thus, interventions that are designed to treat cognitive symptoms are of high priority. Although antipsychotic medications help to treat positive symptoms of schizophrenia, the existing literature demonstrates that they have minimal effects on cognition. Nevertheless, the current studies on procognitive drugs seem to show encouraging results, and different meta-analytic studies have shown the efficacy of cognitive remediation. Several factors could affect cognitive function, and the evidence suggests that one of the main factors could be the cognitive reserve. Higher cognitive reserve is associated with a later onset of psychosis; greater illness insight; and better clinical, cognitive, and functional outcomes in people with schizophrenia. Thus, increasing cognitive reserve could become a skill that will allow people with schizophrenia to cope better with the disease and minimize their decline in cognitive and psychosocial functioning. The present Special Issue aims to go in-depth about the cognitive and functional impairment that people with schizophrenia suffer from and to describe the lines of research that are currently ongoing about enhancers of the cognitive and functional status of people with schizophrenia.

Dr. Iria Grande
Dr. Eduard Vieta
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • functioning
  • schizophrenia
  • negative symptoms
  • cognition
  • procognitive drugs
  • remediation
  • cognitive reserve

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (4 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

18 pages, 1258 KiB  
Article
Polygenic Risk Scores Shed Light on the Relationship between Schizophrenia and Cognitive Functioning: Review and Meta-Analysis
by Jasmina Mallet, Yann Le Strat, Caroline Dubertret and Philip Gorwood
J. Clin. Med. 2020, 9(2), 341; https://doi.org/10.3390/jcm9020341 - 25 Jan 2020
Cited by 28 | Viewed by 4961
Abstract
Schizophrenia is a multifactorial disease associated with widespread cognitive impairment. Although cognitive deficits are one of the factors most strongly associated with functional impairment in schizophrenia (SZ), current treatment strategies hardly tackle these impairments. To develop more efficient treatment strategies in patients, a [...] Read more.
Schizophrenia is a multifactorial disease associated with widespread cognitive impairment. Although cognitive deficits are one of the factors most strongly associated with functional impairment in schizophrenia (SZ), current treatment strategies hardly tackle these impairments. To develop more efficient treatment strategies in patients, a better understanding of their pathogenesis is needed. Recent progress in genetics, driven by large genome-wide association studies (GWAS) and the use of polygenic risk scores (PRS), has provided new insights about the genetic architecture of complex human traits, including cognition and SZ. Here, we review the recent findings examining the genetic links between SZ and cognitive functions in population-based samples as well as in participants with SZ. The performed meta-analysis showed a negative correlation between the polygenetic risk score of schizophrenia and global cognition (p < 0.001) when the samples rely on general and healthy participants, while no significant correlation was detected when the three studies devoted to schizophrenia patients were meta-analysed (p > 0.05). Our review and meta-analysis therefore argues against universal pleiotropy for schizophrenia alleles and cognition, since cognition in SZ patients would be underpinned by the same genetic factors than in the general population, and substantially independent of common variant liability to the disorder. Full article
(This article belongs to the Special Issue Improving Cognitive Functioning in People with Schizophrenia)
Show Figures

Figure 1

15 pages, 312 KiB  
Article
Role of Executive Function in Response to a Problem Solving Based Psychoeducational Intervention in Adolescents with Psychosis: The PIENSA Trial Revisited
by Marta Rapado-Castro, Carmen Moreno, Ana Ruíz-Sancho, Francisco Camino, Celso Arango and Maria Mayoral
J. Clin. Med. 2019, 8(12), 2108; https://doi.org/10.3390/jcm8122108 - 2 Dec 2019
Cited by 4 | Viewed by 3329
Abstract
An improvement in negative symptoms and a reduction in the number of visits to the emergency department have been reported in a problem solving based psychoeducational group intervention (PE) for adolescents with psychosis relative to a nonstructured group (NS). One of the factors [...] Read more.
An improvement in negative symptoms and a reduction in the number of visits to the emergency department have been reported in a problem solving based psychoeducational group intervention (PE) for adolescents with psychosis relative to a nonstructured group (NS). One of the factors that may play a role on the response to PE treatment is executive function (EF), a crucial cognitive domain for problem-solving performance. We aimed to examine the role of EF in response to PE treatment versus an NS group. We examined the associations between changes in cognition and in clinical/functional variables within each treatment group using Spearman-ranked and partial correlation analyses. A total of 22 individuals (mean age: 16.3) were randomized to PE (N = 10) and NS (N = 12). We found an association between improvements in EF performance and a reduction in positive symptoms (rs = –0.756, p = 0.030 for semantic fluency), reduction in negative symptoms (r = 0.758, p = 0.029 for semantic; rs = –0,733, p = 0.025 for verbal fluency), and reduction in the number of visits to the emergency department (r = –0,743, p = 0.035 for semantic fluency) in the PE group. No associations were found in the NS group. Our results suggest that EF may play a role in the specific improvements observed in the PE group. This may have implications in the development of new areas of clinical intervention focusing on the role of cognitive functioning in response to psychosocial treatments in psychosis. Full article
(This article belongs to the Special Issue Improving Cognitive Functioning in People with Schizophrenia)
14 pages, 551 KiB  
Article
Lifetime Psychotic Symptoms, Subthreshold Depression and Cognitive Impairment as Barriers to Functional Recovery in Patients with Bipolar Disorder
by Caterina Mar Bonnín, Esther Jiménez, Brisa Solé, Carla Torrent, Joaquim Radua, María Reinares, Iria Grande, Victoria Ruíz, Jose Sánchez-Moreno, Anabel Martínez-Arán and Eduard Vieta
J. Clin. Med. 2019, 8(7), 1046; https://doi.org/10.3390/jcm8071046 - 18 Jul 2019
Cited by 27 | Viewed by 5401
Abstract
(1) Background: bipolar disorder (BD) is a chronic disease that often leads to functional impairment. The objective of this study is to elucidate which variables are associated with better functional outcomes in a sample of euthymic patients with BD. (2) Methods: patients were [...] Read more.
(1) Background: bipolar disorder (BD) is a chronic disease that often leads to functional impairment. The objective of this study is to elucidate which variables are associated with better functional outcomes in a sample of euthymic patients with BD. (2) Methods: patients were recruited at the Hospital Clinic of Barcelona and they underwent a clinical interview, a functional assessment, and a comprehensive neuropsychological evaluation. After that, patients were divided into two groups according to the Functioning Assessment Short Test total score: functionally remitted vs. functionally impaired. Following this, a multivariate logistic regression was run in order to identify clinical, demographic and cognitive factors associated with functional remission. (3) Results: a total of 420 euthymic patients with BD were assessed for this study, distributed as follows: functionally remitted (n = 221) and functionally impaired (n = 199). Finally, the multivariate logistic regression revealed that only five variables significantly contributed to the model, including: lifetime history of psychotic symptoms (the variable that contributed the most to the model), followed by the Hamilton Depression total score, and cognitive performance (executive functions and verbal memory). (4) Conclusions: treatments to ensure a good functional outcome in BD should specially prevent psychosis, target subthreshold depressive symptoms and enhance cognition, more specifically executive functions and verbal memory. Full article
(This article belongs to the Special Issue Improving Cognitive Functioning in People with Schizophrenia)
Show Figures

Figure 1

19 pages, 1388 KiB  
Article
Cognitive Reserve Assessment Scale in Health (CRASH): Its Validity and Reliability
by Silvia Amoretti, Bibiana Cabrera, Carla Torrent, Caterina del Mar Bonnín, Gisela Mezquida, Marina Garriga, Esther Jiménez, Anabel Martínez-Arán, Brisa Solé, Maria Reinares, Cristina Varo, Rafael Penadés, Iria Grande, Estela Salagre, Eduard Parellada, Miquel Bioque, Clemente Garcia-Rizo, Ana Meseguer, Gerard Anmella, Adriane R Rosa, Fernando Contreras, Gemma Safont, Eduard Vieta and Miquel Bernardoadd Show full author list remove Hide full author list
J. Clin. Med. 2019, 8(5), 586; https://doi.org/10.3390/jcm8050586 - 28 Apr 2019
Cited by 44 | Viewed by 6645
Abstract
(1) Background: The cognitive reserve (CR) concept has not been precisely defined in severe mental disorders and has been estimated using heterogeneous methods. This study aims to investigate and develop the psychometric properties of the Cognitive Reserve Assessment Scale in Health (CRASH), an [...] Read more.
(1) Background: The cognitive reserve (CR) concept has not been precisely defined in severe mental disorders and has been estimated using heterogeneous methods. This study aims to investigate and develop the psychometric properties of the Cognitive Reserve Assessment Scale in Health (CRASH), an instrument designed to measure CR in people with severe mental illness; (2) Methods: 100 patients with severe mental illness (non-affective psychoses and affective disorders) and 66 healthy controls were included. The internal consistency and convergent validity of CRASH were assessed. Spearman’s correlations coefficients were also performed to examine the relationship between CRASH and neuropsychological tests, psychosocial functioning, and clinical course; (3) Results: The internal consistency was high (Cronbach’s alpha coefficient = 0.903). The CRASH global score had a large positive correlation with the Cognitive reserve questionnaire total score (r = 0.838, p < 0.001), demonstrating good convergent validity. The correlation coefficients between the CRASH total scores and clinical, functional, and neuropsychological performance were different between groups. In order to provide clinical interpretation, severity classification based on diagnosis (non-affective psychotic disorders, affective disorders, and healthy controls) have been created; (4) Conclusions: CRASH is the first CR measure developed specifically for patients with severe mental illness, facilitating reliable and valid measurement of this construct. The scale may aid in the stratification of patients and the implementation of personalized interventions. Full article
(This article belongs to the Special Issue Improving Cognitive Functioning in People with Schizophrenia)
Show Figures

Figure 1

Back to TopTop